Literature DB >> 11078269

Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center.

B C Bradley1, K S Perdue, K A Tisdel, D M Gilligan.   

Abstract

Randomized clinical trials have led to guidelines for anticoagulation in atrial fibrillation (AF). However, it is unclear how successfully these guidelines are being implemented in clinical practice and there is concern that anticoagulation is underused. Therefore, we examined the rate of anticoagulation in 998 patients with AF who attended a Veterans Affairs Medical Center over a 2-year period. Warfarin was prescribed for 504 patients (51%) and not prescribed for 494 patients (49%). Of these 494 patients, 446 had sufficient data for further assessment. Warfarin was judged not indicated in 200 because AF was transient or lone. Warfarin was indicated in 246 patients, 63% having > or =3 risk factors for thromboembolism. However, 184 of these patients also had at least 1 contraindication to anticoagulation. Thus, warfarin was prescribed to 67% of patients with AF in whom anticoagulation was indicated and to 89% of such patients in whom it was indicated and who had no contraindications. However, 25% of AF patients with strong indications for anticoagulation had concomitant contraindications, which precluded its use. We conclude that the use of warfarin for AF in this setting is higher than previously reported and approaching ideal levels. However, there remains a large, problematic subgroup of patients with AF in whom indications for and contra-indications to anticoagulation coexist.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11078269     DOI: 10.1016/s0002-9149(99)00813-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

1.  The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.

Authors:  Dorien Groenendaal; Gregory Strabach; Alberto Garcia-Hernandez; Takeshi Kadokura; Marten Heeringa; Roelof Mol; Charlotte Eltink; Hartmut Onkels
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 2.  Antithrombotic treatment in atrial fibrillation.

Authors:  L Kalra; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

3.  Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation.

Authors:  Benjamin A Steinberg; Melissa A Greiner; Bradley G Hammill; Lesley H Curtis; Emelia J Benjamin; Susan R Heckbert; Jonathan P Piccini
Journal:  Cardiovasc Ther       Date:  2015-08       Impact factor: 3.023

4.  What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire.

Authors:  Anders Ingelgård; Jennifer Hollowell; Prabashni Reddy; Karen Gold; Kimbach Tran; David Fitzmaurice
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

5.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

Review 6.  Alternatives to warfarin for thromboembolism prophylaxis in nonrheumatic atrial fibrillation.

Authors:  Ramin Artang; Humberto Vidaillet
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

Review 7.  Do population studies confirm the benefit of oral anticoagulation in atrial fibrillation demonstrated in clinical trials?

Authors:  Rik Willems; Derek V Exner
Journal:  J Interv Card Electrophysiol       Date:  2004       Impact factor: 1.900

Review 8.  Advancement in antithrombotics for stroke prevention in atrial fibrillation.

Authors:  Mohammed Haris Umer Usman; Sabreen Raza; Shariq Raza; Michael Ezekowitz
Journal:  J Interv Card Electrophysiol       Date:  2008-04-17       Impact factor: 1.900

Review 9.  Bleeding risk prediction models in atrial fibrillation.

Authors:  Isac C Thomas; Matthew J Sorrentino
Journal:  Curr Cardiol Rep       Date:  2014-01       Impact factor: 2.931

10.  Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study.

Authors:  Dominique Deplanque; Didier Leys; Lucilla Parnetti; Reinhold Schmidt; Jose Ferro; Jacques De Reuck; Jean-Louis Mas; Virgilio Gallai
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.